CD22 and acute lymphoblastic leukemia: Moreover, radioimmunotherapy with yttrium-90-labelled epratuzumab tetraxetan (90Y-DOTA-epratuzumab) in adults with r/r CD22+ precursor B-ALL was associated with IFDs in 11.8% and with severe infections in 52.9% of patients [68].